Grégory Behar

Grégory Behar currently works at Recipharm AB, as Chief Executive Officer from 2024, Nestle Health Science SA (Private Equity), as President & CEO from 2014, Recipharm Karlskoga AB, as Chief Executive Officer from 2024, Recipharm Pharmaceutical Development AB, as Chief Executive Officer from 2024, Nutrition Science Partners Ltd., as Chairman, Sonova Holding AG, as Independent Non-Executive Director from 2021, Prometheus Laboratories, Inc., as Director, Amazentis SA, as Director, and Nestlé Health Science (Deutschland) GmbH, as Member-Supervisory Board.
Mr. Behar also formerly worked at Boehringer Ingelheim Pharmaceuticals, Inc., as President & Chief Executive Officer from 2011 to 2014, Nestle Health Science SA, as Chief Executive Officer, Nestlé Health Science France SAS, as Chief Executive Officer, Cerecin, Inc., as Director, Seres Therapeutics, Inc., as Independent Director from 2014 to 2023, Axcella Health, Inc., as Independent Director from 2016 to 2022, Aimmune Therapeutics, Inc., as Independent Director from 2016 to 2020, Prometheus Biosciences, Inc., as Director, Boehringer Ingelheim GmbH, as Vice President-NECAR Region from 2010 to 2011, and Nestlé SA, as Manager in 2000.
Mr. Behar received his graduate degree from École Polytechnique Fédérale de Lausanne, undergraduate degree from the University of California, Los Angeles, and Masters Business Admin degree from INSEAD.